Consolidation ALK Tyrosine Kinase Inhibitors versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK+ Non-Small Cell Lung Cancer

By sjmartinez • September 12, 2024

Nassar AH, Jayakrishnan R, Feng J, Shepherd F, Adib E, Cheung JM, Lin JJ, Liu Y, Lin SH, Parikh K, Sridhar A, Shakya P, Dilling TJ, Kaldas D, Gray JE, Lobachov A, Bar J, Luders H, Grohe C, Gupta S, Leal T, Fitzgerald B, Crowley F, Fujiwara Y, Marron TU, Wilgucki M, Reuss J, Chen L, Sankar K, Aredo JV, Neal JW, Wakelee HA, Thummalapalli R, Yu H, Whitaker R, Velazquez A, Ragavan M, Cortellini A, Kwiatkowski DJ, Naqash AR, Goldberg SB, Kim SY. Consolidation ALK Tyrosine Kinase Inhibitors versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK+ Non-Small Cell Lung Cancer. J Thorac Oncol. 2024 Sep 9:S1556-0864(24)02265-2. doi: 10.1016/j.jtho.2024.09.1379. Epub ahead of print. PMID: 39260522.

Tags: Cedars Sinai DoM, Hematology/Oncology, Publications

Opportunistic Screening of Chronic Liver Disease with Deep-Learning-Enhanced Echocardiography

Sahashi Y, Vukadinovic M, Amrollahi F, Trivedi H, Rhee J, Chen J, Cheng S, Ouyang D, Kwan AC. Opportunistic Screening of Chronic Liver Disease with[...]

Inflammation and dimensions of fatigue in women with early stage breast cancer: A longitudinal examination

Bower JE, Radin A, Ganz PA, Irwin MR, Cole SW, Petersen L, Asher A, Hurvitz SA, Crespi CM. Inflammation and dimensions of fatigue in women[...]

Serum soluble mediator signatures of lupus nephritis: histological features and response to treatment

Fava A, Wagner CA, Guthridge CJ, Macwana S, DeJager W, Munroe ME, Izmirly P, Belmont HM, Diamond B, Davidson A, Utz PJ, Weisman MH, Carlucci[...]